Cargando…
The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling
Obesity and nonalcoholic fatty liver disease (NAFLD) are global health concerns, and thus, drugs for the long-term treatment of these diseases are urgently needed. We previously discovered that the inositol pyrophosphate biosynthetic enzyme IP6K1 is a target in diet-induced obesity (DIO), insulin re...
Autores principales: | Mukherjee, Sandip, Chakraborty, Molee, Haubner, Jake, Ernst, Glen, DePasquale, Michael, Carpenter, Danielle, Barrow, James C., Chakraborty, Anutosh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216446/ https://www.ncbi.nlm.nih.gov/pubmed/37238737 http://dx.doi.org/10.3390/biom13050868 |
Ejemplares similares
-
Whole Body Ip6k1 Deletion Protects Mice from Age-Induced Weight Gain, Insulin Resistance and Metabolic Dysfunction
por: Ghoshal, Sarbani, et al.
Publicado: (2022) -
Targeting the Inositol Pyrophosphate Biosynthetic Enzymes in Metabolic Diseases
por: Mukherjee, Sandip, et al.
Publicado: (2020) -
Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis
por: Mukherjee, Sandip, et al.
Publicado: (2021) -
TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway
por: Ghoshal, Sarbani, et al.
Publicado: (2016) -
Ube4A maintains metabolic homeostasis and facilitates insulin signaling in vivo
por: Mukherjee, Sandip, et al.
Publicado: (2023)